RxDoctor Payments Data

Felix Cerna

Infectious Disease · Albuquerque, NMNPI 1982664884

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.7% of the total across 137 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Gilead at 24.4% of the total. Reporting peaked in 2019 at $674 and has fallen 92.4% since, to $51 in 2025.

$2,366in general payments, 2019–2025

Across 137 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$577
  • Viiv Healthcare Company$435
  • Merck$382
  • AbbVie$358
  • Astellas Pharma US Inc$178
  • GSK$136
  • plus $300 from 12 others

What the payments were for

  • Food & beverage$2,33599%
  • Education$311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,366 in reported general payments places this provider in the 80th percentile of 31 infectious disease providers in New Mexico.

See all infectious disease providers in New Mexico

Other infectious disease in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →